Chewy Announces Fiscal Third Quarter 2019 Financial Results Conference Call
Get Alerts CHWY Hot Sheet
Join SI Premium – FREE
DANIA BEACH, Fla--(BUSINESS WIRE)-- Chewy, Inc. (NYSE: CHWY) (“Chewy”), a trusted online destination for pets and pet parents, today announced it will report fiscal third quarter 2019 financial results after the market close on Monday, December 9, 2019. Management will host a conference call and webcast to discuss the Company's financial results at 5:00 pm ET.
Chewy Fiscal Third Quarter 2019 Financial Results Conference Call
When: Monday, December 9, 2019
Time: 5:00 pm ET
Conference ID: 6988718
Live Call: (866) 393-4306 (US/Canada Toll-Free) or (734) 385-2616 (International)
Replay: (855) 859-2056 (US/Canada Toll-Free) or (404) 537-3406 (International)
(The replay will be available approximately two hours after the completion of the live call until 11:59 pm ET on December 16, 2019)
Webcast: https://investor.chewy.com
About Chewy
Our mission is to be the most trusted and convenient online destination for pet parents everywhere. We believe that we are the preeminent online source for pet products, supplies and prescriptions as a result of our broad selection of high-quality products, which we offer at competitive prices and deliver with an exceptional level of care and a personal touch. We continually develop innovative ways for our customers to engage with us, and partner with more than 1,700 of the best and most trusted brands in the pet industry to bring a high-bar, customer-centric experience to our customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005154/en/
Media Contact:
[email protected]
Investor Contact:
Kelsey Turcotte
[email protected]
Source: Chewy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HASI Announces First Quarter 2024 Earnings Release Date and Conference Call
- Farmers National Banc Corp. Announces Strong Results for First Quarter of 2024
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!